文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

D-乳酸与肠脂肪酸结合蛋白评估ICU患者病情严重程度及预后的临床研究:一项前瞻性多中心临床研究的二次分析

[Clinical study of D-lactate and intestinal fatty acid binding protein in evaluating disease severity and prognosis of ICU patients: secondary analysis of a prospective, multicenter clinical study].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论ICU患者血清D-乳酸和I-FABP显著升高,动态变化与病情改善及28天预后相关,但单独预测价值有限(AUC 0.634–0.652)。

本研究为对一项前瞻性、随机、单盲、多中心临床研究的二次分析,纳入华南7个ICU的141例患者及15名健康志愿者,比较血清D-乳酸和I-FABP在ICU患者与健康对照间的差异,并分析其与APACHE II、SOFA评分及28天预后的相关性。结果显示ICU患者第0天D-乳酸和I-FABP显著高于健康对照(均P<0.01),第5天下降但仍高于对照;第5天D-乳酸和I-FABP在病情改善组显著低于未改善组(均P<0.05);第5天D-乳酸及第0、5天I-FABP对28天预后有独立预测价值,AUC分别为0.634、0.638、0.652。提示两指标有一定预后预测价值,但 discriminative 能力有限。

要点

  • ICU患者第0天D-乳酸和I-FABP显著高于健康志愿者(均P<0.01),第5天下降但仍高于健康对照。
  • 第5天D-乳酸和I-FABP在病情改善组(101例)显著低于未改善组(40例)(均P<0.05)。
  • 第5天D-乳酸与第0、5天I-FABP对28天预后有独立预测价值,AUC分别为0.634、0.638、0.652。
  • cut-off值:第5天D-乳酸7.71 mg/L(敏感度51.5%,特异度91.0%);第0天I-FABP 593.55 ng/L(敏感度68.5%,特异度60.0%);第5天I-FABP 468.10 ng/L(敏感度75.3%,特异度60.0%)。
  • D-乳酸第0、5天与APACHE II和SOFA评分显著正相关(R²=0.367,P<0.001;R²=0.240,P=0.012)。

适用人群与场景

  • 纳入华南7个ICU的141例ICU患者,以及15名健康志愿者作为健康对照。
  • 患者来源为一项评估脂肪改良肠内营养悬液对肠道屏障影响的前瞻性、随机、单盲、多中心临床研究的二次分析。
  • 排除人群、急诊/院前场景及病情阶段原文未提及。

诊断标准与关键阈值

  • 第0天定义为肠内营养达到500 mL的前一天;第5天定义为肠内营养≥2 092 kJ/d持续5天。
  • 根据第5天(与第0天相比)血流动力学和/或机械通气状态,将141例患者分为改善组(101例)和未改善组(40例)。
  • 预后指标为28天预后;病情严重程度采用APACHE II评分、SOFA评分、C反应蛋白(CRP)及初始ICU诊断评估。

处置流程与药物剂量

  • 原文未提及基于D-乳酸或I-FABP的具体治疗干预或药物剂量调整方案。

红旗征与不能漏的情况

  • 原文未提及需要立刻处理或不能漏诊的红旗征及对应处理。

研究设计与关键结果

  • 研究类型:前瞻性、随机、单盲、多中心临床研究的二次分析(采用回顾性分析方法);样本量141例ICU患者(7个ICU)及15名健康志愿者。
  • 与健康志愿者相比,ICU患者第0天血清D-乳酸和I-FABP显著升高[D-乳酸(mg/L):10.82(3.31,25.48)vs. 6.63(1.54,17.70);I-FABP(ng/L):519.60(159.06,1 362.14)vs. 84.40(30.78,108.57),均P<0.01];第5天两者较第0天下降,但仍高于健康志愿者。
  • 改善组第0天I-FABP显著低于未改善组,D-乳酸两组间无显著差异;两组第5天D-乳酸和I-FABP均较第0天显著下降,且改善组第5天D-乳酸和I-FABP显著低于未改善组[D-乳酸(mg/L):7.61(1.71,27.22)vs. 9.38(2.09,20.56);I-FABP(ng/L):378.65(152.56,864.62)vs. 521.21(205.93,1 413.11),均P<0.05]。
  • 相关性:第0天和第5天D-乳酸与APACHE II评分和SOFA评分显著正相关(R²=0.367,P<0.001;R²=0.240,P=0.012);第0天I-FABP与APACHE II评分显著正相关(R²=0.264,P=0.004);第5天D-乳酸及第0、5天I-FABP与28天预后显著负相关(R²=-0.203,P=0.022;R²=-0.208,P=0.023;R²=-0.211,P=0.021)。
  • AUC分析:第5天D-乳酸、第0天I-FABP、第5天I-FABP对28天预后有独立预测价值,AUC分别为0.634(95%CI 0.533–0.734,P=0.023)、0.638(95%CI 0.523–0.754,P=0.024)、0.652(95%CI 0.525–0.778,P=0.017);cut-off值分别为7.71 mg/L、593.55 ng/L、468.10 ng/L,敏感度分别为51.5%、68.5%、75.3%

证据类型、等级与局限

  • 证据类型:前瞻性、随机、单盲、多中心临床研究的二次分析(原文采用回顾性分析方法)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:二次分析、样本量141例、仅华南7个ICU、健康对照仅15例;原文未提及其他局限。

对床旁实践的改变

  • 原文提示血清D-乳酸和I-FABP在ICU患者中显著升高并随病情改善而下降,可辅助评估病情严重程度及28天预后,但AUC 0.634–0.652提示单独预测价值有限,不应作为唯一决策依据。
  • 原文未提及基于这些生物标志物的具体治疗改变、适用与不适用人群及常见陷阱。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To analyze the relationship between D-lactate, intestinal fatty acid binding protein (I-FABP) and the severity as well as the prognosis of patients in intensive care unit (ICU).

METHODS: Using a retrospective approach, the data derived from a prospective, randomized, single-blind, multicenter clinical study published earlier by our group were further analyzed to evaluate the effect of fat-modified enteral nutrition (EN) suspension on the intestinal barrier in ICU patients. In this study, a total of 141 patients were recruited from 7 ICUs in South China, and 15 healthy volunteers were included as healthy control group. Clinical data of patients were collected, including gender, age, disease severity related indicators such as acute physiology and chronic health evaluation II (APACHE II), sequential organ failure assessment (SOFA), C-reactive protein (CRP) and initial ICU diagnosis, as well as prognostic indicators such as length of stay in ICU, length of stay in hospital and prognosis of patients at 28 days. To compare the difference of serum D-lactate and I-FABP between ICU patients and healthy control group on day 0 (the day before EN reached 500 mL) and day 5 (EN ≥ 2 092 kJ/d for 5 days). According to the hemodynamic and/or mechanical ventilation status on day 5 (compared with day 0), 141 patients were divided into the improvement group (101 cases) and the non-improvement group (40 cases), and the changes of D-lactate and I-FABP in the two groups were observed. Spearman correlation analysis was used to analyze the correlation between serum D-lactate, I-FABP and the severity of the disease, as well as the predictive value of dynamic changes of D-lactate and I-FABP on the prognosis of 28 days.

RESULTS: Compared with the healthy volunteers, the serum D-lactate and I-FABP levels of ICU patients on day 0 were significantly increased [D-lactate (mg/L): 10.82 (3.31, 25.48) vs. 6.63 (1.54, 17.70), I-FABP (ng/L): 519.60 (159.06, 1 362.14) vs. 84.40 (30.78, 108.57), both P < 0.01], and D-lactate and I-FABP on day 5 were both decreased compared with the levels on day 0, but still higher than the healthy volunteers. I-FABP in the improvement group was significantly lower than that in the non-improvement group on day 0, and there was no significant difference in D-lactate levels between the two groups, D-lactate and I-FABP in both groups were significantly lower on day 5 than those on day 0, and D-lactate and I-FABP in the improvement group on day 5 were significantly lower than those in the non-improvement group [D-lactate (mg/L): 7.61 (1.71, 27.22) vs. 9.38 (2.09, 20.56), I-FABP (ng/L): 378.65 (152.56, 864.62) vs. 521.21 (205.93, 1 413.11), all P < 0.05]. Correlation analysis showed that D-lactate was significantly positively correlated with APACHE II score and SOFA score on day 0 and day 5 (R12 = 0.367, P < 0.001; R22 = 0.240, P = 0.012); I-FABP was significantly positively correlated with APACHE II score on day 0 (R2 = 0.264, P = 0.004); D-lactate on day 5 and I-FABP on day 0 and day 5 were significantly negatively correlated with prognosis on day 28 (R12 = -0.203, P = 0.022; R22 = -0.208, P = 0.023; R32 = -0.211, P = 0.021). The area under curve (AUC) analysis showed that D-lactate on day 5 and I-FABP on day 0 and day 5 had independent predictive value for 28-day prognosis, with AUC of 0.634, 0.638 and 0.652, P values of 0.023, 0.024 and 0.017, 95% confidence intervals (95%CI) of 0.533-0.734, 0.523-0.754 and 0.525-0.778, respectively. When the cut-off values were 7.71 mg/L, 593.55 ng/L and 468.10 ng/L, the sensitivity were 51.5%, 68.5% and 75.3%, and the specificity were 91.0%, 60.0% and 60.0%, respectively.

CONCLUSIONS: Serum D-lactate and I-FABP were increased significantly and decreased with the improvement of the condition, and these two molecular biomarkers have certain value in predicting the prognosis of ICU patients.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Qiu C, Wang L, Chen C, et al. [Clinical study of D-lactate and intestinal fatty acid binding protein in evaluating disease severity and prognosis of ICU patients: secondary analysis of a prospective, multicenter clinical study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 33463492. doi:10.3760/cma.j.cn121430-20200929-00613

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。